LGND Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Ligand Pharmaceuticals Inc (LGND) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong technical indicators, positive analyst sentiment, and recent congressional buying, which aligns with a favorable long-term outlook. Despite being overbought in the short term, the stock's fundamentals and catalysts suggest significant upside potential.
The stock is in a strong bullish trend with MACD positively expanding, RSI at 92.771 indicating overbought conditions, and bullish moving averages (SMA_5 > SMA_20 > SMA_200). The price is above key resistance levels, with the next resistance at 279.773.
Analyst upgrades with increased price targets and Buy ratings due to strategic acquisitions and FDA approvals.
Congressional purchase of $0.8M, indicating confidence in the stock.
Strong royalty potential from Filspari and a growing developmental pipeline.
Insider selling by Director John W. Kozarich, who sold 5.65% of his holdings.
Overbought RSI suggests potential short-term pullback.
No financial data available for the latest quarter.
Analysts are highly bullish, with multiple Buy ratings and price targets ranging from $252 to $289. Recent upgrades are driven by strategic acquisitions and FDA approvals, which are expected to drive long-term growth.
